Healthcare / Medical DistributionIstanbul
$98.90
+0.10 (+0.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$61.4B
P/E
52.9x
↑EV/EBITDA
18.6x
↑ROE
-1.3%
↓Gross Margin
8.3%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+26.4%
FCF CAGR
—
FCF margin
3.7%
FCF / Net income
-16.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $172.01B · net income $-379.8M · FCF $6.37B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $172.01B | $172.01B | $168.35B | $141.09B | $85.20B |
| Net Income | $-379.8M | $-379.8M | $2.69B | $322.3M | $635.7M |
| EBITDA | $3.28B | $3.28B | $8.19B | $3.34B | $1.49B |
| EPS | -0.61 | -0.61 | 4.34 | 0.52 | 1.02 |
| Gross Margin | 8.3% | 8.3% | 10.1% | 9.4% | 10.4% |
| Operating Margin | 2.2% | 2.2% | 4.2% | 4.7% | 5.6% |
| Net Margin | -0.2% | -0.2% | 1.6% | 0.2% | 0.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.34 | 0.16 | 0.03 |
| Current Ratio | 1.37 | 1.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.37B | $6.37B | $-12.22B | $1.70B | $-1.40B |
| Returns | |||||
| ROE | -1.3% | -1.3% | 8.8% | 1.5% | 4.2% |
| Valuation | |||||
| P/E | 52.89 | 52.89 | 18.94 | 111.27 | 39.63 |
| EV/EBITDA | 18.61 | 18.61 | 7.02 | 9.86 | 16.44 |
| P/B | 2.05 | 2.05 | 1.66 | 1.65 | 1.66 |
| Growth & Yield | |||||
| Revenue Growth | 2.2% | 2.2% | 19.3% | 65.6% | — |
| EPS Growth | -114.1% | -114.1% | 736.0% | -49.3% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+37.1%
Start / end P/E
n/dx → n/dx
EPS bridge
4.34 → -0.61
Residual
+36.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.